Neisserial vaccine compositions and methods

Details Neisserial vaccine compositions and methods Neisserial vaccine compositions and methods

2006-07-25

2006-07-25

Devi, S. (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S249100, C424S250100, C424S203100, C424S200100, C424S184100, C514S002600, C530S350000, C530S825000

Reexamination Certificate

active

07081244

ABSTRACT:
Methods and compositions for the treatment of microbial infection, and in particular meningococcal disease, comprise a commensalNeisseriaor an extract of a commensalNeisseria. Further methods and compositions comprise conimensalNeisseriawhich express genes from virulent strains ofNeisseriaand/or heterologous gene products from non-Neisserial sources. Such compositions are used in vaccine preparations for the treatment of microbial infection.

REFERENCES:
patent: 5470740 (1995-11-01), Longo et al.
patent: 5980912 (1999-11-01), Podolski et al.
patent: 6013267 (2000-01-01), Blake et al.
patent: 6413768 (2002-07-01), Galen
patent: 6703233 (2004-03-01), Galen
patent: 6737521 (2004-05-01), Fischetti et al.
patent: 2003/0021812 (2003-01-01), Robinson et al.
patent: 2003/0026809 (2003-02-01), Robinson et al.
patent: 2003/0215469 (2003-11-01), Robinson et al.
patent: 1 297 844 (2003-04-01), None
patent: WO 96/29412 (1996-09-01), None
patent: WO 99/61620 (1999-12-01), None
patent: WO 03/051379 (2003-06-01), None
Ferreiros et al. FEMS Microbiol. Lett. 83: 247-254, 1991.
Russell et al. Can. J. Microbiol. 21: 1519-1534, 1975.
Kim et al. Infect. immun. 57: 602-608, 1989.
Hoen et al. Infect. immun. 58: 3929-3933, 1990.
Cann, K. J. and Rogers, T.R., “Detection of antibodies to common antigens of pathogenic and commensal Neisseria species,”J. Med. Microbiol. 30:23-30, The Pathological Society of Great Britain and Ireland (1989).
Gómez, J.A. et al., “Antigenicity, cross-reactivity and surface exposure of theNeisseria meningitidis37 kDa protein (Fbp),”Vaccine 14:1340-1346, Elsevier Science Ltd (1996).
English abstract of Aoun, L. et al., “Human Antibody Response to the 70-KD Common Neisserial Antigen in Patients and Carriers ofMeningococcior Non-PathogenicNeisseria,” Annales de l'Institut Pasteur Microbiology 139:203-212, Biosis Online accession No. PREV198886026860, XP-0021498186(1988).
Troncoso, G. et al., “Antigenic cross-reactivity between outer membrane proteins ofNeisseria meningitidisand commensalNeisseriaspecies,”FEMS Immunol. Med. Microbiol. 27:103-109, Elsevier Science B.V. (Feb. 2000).
Ala'Aldeen, D.A.A., “Transferrin receptors ofNeisseria meningitidis: promising candidates for a broadly cross-protective vaccine,”J. Med. Microbiol. 44:237-243, Lippincott, Williams & Wilkins (1996).
Evans, T.M., “Molecular Cloning and Characterization of an Oxygen-Regulated Gonococcal Outer Membrane Protein,”Dissertation Abstracts International 50:3315, The University of Rochester (1989).
Fusco, P.C., et al., “Meningococcal vaccine development: a novel approach,”Exp. Opin. Invest. Drugs 7:245-252, Ashley Publications Ltd. (Feb. 1998).
Gómez, J.A., et al., “Effect of adjuvants in the isotypes and bactericidal activity of antibodies against the transferrin-binding proteins ofNeisseria meningitidis,”Vaccine 16:1633-1639, Elsevier Science Ltd. (Oct. 1998).
Grifantini, R., et al., “Gene Expression Profile inNeisseria meningitidisandNeisseria lactamicaupon Host-Cell Contact,”Ann. N.Y. Acad. Sci. 975:202-216, New York Academy of Sciences (Dec. 2002).
Linz, B., et al., “Frequent interspecific genetic exchange between commensal neisseriae andNeisserle meningitidis,” Molec. Microbiol. 36:1049-1058, Blackwell Science Ltd. (Jun. 2000).
Martin, D., et al., “Highly ConservedNeisseria meningitidisSurface Protein Confers Protection against Experimental Infection,”J. Exp. Med. 185:1173-1183, The Rockefeller University Press (1997).
Moe, G.R., et al., “Differences in Surface Expression of NspA amongNeisseria meningitidisGroup B Strains,”Infection&Immunity 67:5664-5675, American Society for Microbiology (November 1999).
Moe, G.R., et al., “Molecular mimetics of polysaccharide epitopes as vaccine candidates for prevention ofNeisseria meningitidisserogroup B disease,”FEMS Immunol. Med. Microbiol. 26:209-226, Elsevier Science B.V. (Dec. 1999).
Moe, G.R., et al., “Sequential Immunization with Vesicles Prepared from HeterologusNeisseria meningitidisStrains Elicits Broadly Protective Serum Antibodies to Group B Strains,”Infect.&Immun. 70:6021-6031, American Society for Microbiology (Nov. 2002).
Oliver, K.J., et al., “Neisseria lactamicaProtects against Experimental Meningococcal Infection,”Infect.&Immun. 70:3621-3626, American Society for Microbiology (Jul. 2002).
Pannekoek, Y., et al., “Construction of recombinat neisserial Hsp60 proteins and mapping of antigenic domains,”Molec. Microbiol. 15:277-285, Blackwell Science Ltd. (1995).
Parkhill, J., et al., “Complete DNA sequence of a serogroup A strain ofNeisseria meningitidisZ2491,”Nature 404:502-506, Macmillan Publishers Ltd. (Mar. 2000).
Pettit, R.K., et al., “Acid stress upregulated outer membrane proteins in clinical isolates ofNeisseria gonorrhoeae, but not most commensal Neisseria,”Can. J. Microbiol. 47:871-876, National Research Council of Canada (Sep. 2001).
Zhou, J., et al., “Interspecies recombination, and phylogenetic distortions, within the glutamine synthetase and shikimate dehydrogenase genes ofNeisseria meningitidisand commensalNeisseria species,” Molec. Microbiol. 23:799-812, Blackwell Science Ltd. (1997).
Copy of Office Action for U.S. Appl. No. 09/942,583, Robinson et al., filed Aug. 31, 2001, mailed May 8, 2003.
Copy of Office Action for U.S. Appl. No. 09/942,583, Robinson et al., filed Aug. 31, 2001, mailed Jan. 5, 2004.
Copy of Office Action for U.S. Appl. No. 09/942,583, Robinson et al., filed Aug. 31, 2001, mailed Jul. 28, 2004.
Aho, E.L., et al., “A comparative analysis of pilin genes from pathogenic and nonpathogenicNeisseriaspecies,”Microbial Pathogenesis 28:81-88, Academic Press (Feb. 2000).
Aho, E.L., et al., “Characterization of a Class II Pilin Expression Locus fromNeisseria meningitidis: Evidence for Increased Diversity among Pilin Genes in PathogenicNeisseriaSpecies,”Infection and Immunity 65:2613-2620, American Society for Microbiology (1997).
Bennett, J.S., et al., “Genetic Diversity and Carriage Dynamics ofNeisseria lactamicain Infants,”Infection and Immunity 73:2424-2432, American Society for Microbiology (Apr. 2005).
Claassen, I., et al., “Production, characterization and control of aNeisseria meningitidishexavalent class 1 outer membrane protein containing vesicle vaccine,”Vaccine 14:1001-1008, Elsevier Science Ltd. (1996).
Ellis, R.W., “New technologies for making vaccines,”Vaccine 17:1596-1604, Elsevier Science Ltd. (1999).
Goh, L.L., et al., “Molecular cloning and functional characterization of fumarase C inNeisseriaspecies,”Antoine van Leeuwenhoek. 87:205-213, Springer (Apr. 2005).
Gooringe, A., et al., “The development of a meningococcal disease vaccine based onNeisseria lactamicaouter membrane vesicles,”Vaccine 23:2210-2213, Elsevier Science Ltd. (Mar. 2005).
Gotschlich, E.C., et al., “Cloning of the Structural Genes of Three H8 Antigens and of Protein III of Neisseria Gonorrhoeae,”J. Exp. Med. 164:868-881 (1986).
Humphries, H.E., et al., “Recombinant meningococcal PorA protein, expressed usinng a vector system with potential for human vaccination, induces a bactericidal immune response,”Vaccine 22:1564-1569, Elsevier science Ltd. (Mar. 2004).
Jódar, L., et al., “Development of vacines against meningococcal disease,”Lancet 359:1499-1508, The Lancet Publishing Group (Apr. 2002).
Johnson, S.R., et al., “Cloning and Characterization of the Catalase Gene ofNeisseria gonorrhoeae: Use of the Gonococcus as a Host Organism for Recombinant DNA,”Infection and Immunity 64:2627-2634, American Society for Microbiology (1996).
Locht, C., “Live bacterial vectors for intranasal delivery of protective antigens,”PSTT 3:121-128, Elsevier Science (Apr. 2000).
Medaglini, D., et al., “Comm

Affiliated with

Also associated with

Rating

Neisserial vaccine compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Neisserial vaccine compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neisserial vaccine compositions and methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3593824